In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on CareDx (CDNA – Research Report), with a price target of ...
BRISBANE, Calif., March 11, 2025--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of ...
Hosted on MSN1mon
CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?CareDx CDNA shares ended the last trading session 11.2% higher at $24.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.
Baron Discovery Fund highlighted stocks like CareDx, Inc (NASDAQ:CDNA) in the second quarter 2024 investor letter.
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox ...
CareDx (CDNA) announced that AlloSure is now commercially available for pediatric heart transplant patients of all ages and patients who have ...
Through laboratory techniques that track quantities of mRNA, scientists can identify which genes are “turned on” and which are “turned off” in an organism’s tissue at a given time, as ...
CareDx Inc (CDNA) reports a robust 32% revenue increase and strategic expansions, while navigating potential challenges in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback